Toutes les photos(1)

Key Documents

Y0000009

Fluphenazine enantate

Name: Fluphenazine enantate
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

2-[4-[3-[2-(Trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl heptanoate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):

C₂₉H₃₈F₃N₃O₂S

Numéro CAS:

2746-81-8

Poids moléculaire :

549.69

Code UNSPSC :

41116107

Nomenclature NACRES :

NA.24

Qualité

pharmaceutical primary standard

Famille d'API

fluphenazine

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

InChI

1S/C29H38F3N3O2S/c1-2-3-4-5-11-28(36)37-21-20-34-18-16-33(17-19-34)14-8-15-35-24-9-6-7-10-26(24)38-27-13-12-23(22-25(27)35)29(30,31)32/h6-7,9-10,12-13,22H,2-5,8,11,14-21H2,1H3

Clé InChI

LRWSFOSWNAQHHW-UHFFFAOYSA-N

Catégories apparentées

Étalons de référence analytiques | Sigma-Aldrich

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fluphenazine enantate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit

Description

Tarif

1282026

Pictogrammes

GHS06,GHS08

Mention d'avertissement

Danger

Mentions de danger

H301,H360

Conseils de prudence

P201 - P301 + P310 + P330

Classification des risques

Acute Tox. 3 Oral - Repr. 1A

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.

G Chouinard et al.

The American journal of psychiatry, 139(3), 312-318 (1982-03-01)

Vitiligo-like syndrome following the use of fluphenazine enanthate.

M P Rampertaap

Missouri medicine, 82(1), 24-26 (1985-01-01)

Clinical pharmacokinetics of the depot antipsychotics.

M W Jann et al.

Clinical pharmacokinetics, 10(4), 315-333 (1985-07-01)

The clinical pharmacokinetics of the 4 depot antipsychotics for which plasma level studies are available (i.e. fluphenazine enanthate and decanoate, haloperidol decanoate, clopenthixol decanoate and flupenthixol decanoate) are reviewed. The proper study of these agents has been handicapped until recently

Plasma levels of neuroleptic in patients receiving depot fluphenazine.

B M Cohen et al.

Journal of clinical psychopharmacology, 5(6), 328-332 (1985-12-01)

Depot forms of fluphenazine are frequently used in the outpatient treatment of psychiatric patients. To gather relevant data on pharmacokinetic characteristics of depot fluphenazines, the authors measured plasma levels of neuroleptic activity in 76 clinic patients on stable dosage regimens

The use of depot neuroleptics: clinical experience in the United States.

J M Kane

The Journal of clinical psychiatry, 45(5 Pt 2), 5-12 (1984-05-01)

The use of long-acting injectable preparations such as fluphenazine enanthate or decanoate can reduce patient noncompliance, but documenting this in a controlled research design is difficult. Several studies of relapse rates among patients receiving oral fluphenazine, depot fluphenazine, or placebo

Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique